BioMarin Pharmaceutical Q3 Earnings Call Highlights
Published . Updated .
BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while
Directly affected
- BMRN Biomarin Pharmaceutical-8.6% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+4.0% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BMRN | -3.66% | -0.09% | base | after close | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| XBINo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
BioMarin Pharmaceutical Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
How far Select Sector Spdr Tr (XLV) has moved since 3 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| BMRN | three days earlier | -0.09% | final price |
| BMRN | five days earlier | -3.66% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “BioMarin Pharmaceutical Q3 Earnings Call Highlights.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “BioMarin Pharmaceutical Q3 Earnings Call Highlights.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
In “BioMarin Pharmaceutical Q3 Earnings Call Highlights,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “BioMarin Pharmaceutical Q3 Earnings Call Highlights.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
In “BioMarin Pharmaceutical Q3 Earnings Call Highlights,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- MRK Merck
In “BioMarin Pharmaceutical Q3 Earnings Call Highlights,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
How “BioMarin Pharmaceutical Q3 Earnings Call Highlights” reaches Select Sector Spdr Tr (XLV)
On 3 Nov 2026, “BioMarin Pharmaceutical Q3 Earnings Call Highlights” is the story that connects Select Sector Spdr Tr (XLV) to this story.
Select Sector Spdr Tr (XLV) is on the page because Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1415.62.
What the saved facts support for Select Sector Spdr Tr (XLV)
46 out of 100
“BioMarin Pharmaceutical Q3 Earnings Call Highlights” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.